SequelSEC

Alto Neuroscience, Inc. ANRO

Pharmaceutical Preparations · CIK 0001999480 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-06-30
Operating income
-$29.13M
Fiscal year ended 2026-06-30
Free cash flow
-$19.76M
Fiscal year ended 2026-06-30

Alto Neuroscience, Inc. (ANRO) reported net income of -$27.64M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Alto Neuroscience, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Alto Neuroscience, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$29.13MUnavailable-$17.06M-$14.95MUnavailableUnavailable-$17.00M-$18.89MUnavailableUnavailable
Net income-$27.64MUnavailable-$16.18M-$14.18MUnavailableUnavailable-$15.20M-$16.78MUnavailableUnavailable
Research & development$22.11MUnavailable$12.00M$10.52MUnavailableUnavailable$10.80M$13.06MUnavailableUnavailable
Weighted-average diluted sharesshares 42.81MUnavailableUnavailableshares 27.10MUnavailableUnavailableUnavailableshares 26.96MUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expenseUnavailableUnavailable$0$0UnavailableUnavailable$0$0UnavailableUnavailable
Diluted EPS$-0.65UnavailableUnavailable$-0.52UnavailableUnavailableUnavailable$-0.62UnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$7.02MUnavailable$5.06M$4.43MUnavailableUnavailable$6.20M$5.83MUnavailableUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Alto Neuroscience, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Cash & equivalents$243.73MUnavailable$176.48M$137.82MUnavailableUnavailable$168.23M$181.70MUnavailableUnavailable
Total assets$254.07MUnavailable$184.69M$147.01MUnavailableUnavailable$177.54M$191.61MUnavailableUnavailable
Current assets$247.32MUnavailable$177.72M$139.45MUnavailableUnavailable$169.34M$183.53MUnavailableUnavailable
Total liabilities$34.82MUnavailable$33.55M$35.45MUnavailableUnavailable$26.08M$26.56MUnavailableUnavailable
Current liabilities$16.65MUnavailable$11.32M$9.04MUnavailableUnavailable$10.01M$14.02MUnavailableUnavailable
Total equity incl. NCI$219.25MUnavailable$151.14M$111.56MUnavailableUnavailable$151.46M$165.05MUnavailableUnavailable
Temporary (mezzanine) equityUnavailableUnavailable$0$0UnavailableUnavailable$0$0UnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$12.42MUnavailable$16.17M$20.31MUnavailableUnavailable$10.25M$6.63MUnavailableUnavailable
Accounts payable$4.02MUnavailable$1.88M$2.06MUnavailableUnavailable$1.58M$2.25MUnavailableUnavailable

Cash flow

Alto Neuroscience, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Operating cash flow-$19.76MUnavailable-$11.52M-$9.92MUnavailableUnavailable-$13.02M-$11.73MUnavailableUnavailable
Capital expenditures$0Unavailable$0$0UnavailableUnavailable$506.00K$1.00MUnavailableUnavailable
Investing cash flow$0Unavailable$0$0UnavailableUnavailable-$506.00K-$1.00MUnavailableUnavailable
Financing cash flow-$273.00KUnavailable$50.18M$153.00KUnavailableUnavailable$49.00K$1.32MUnavailableUnavailable
Net change in cash-$20.03MUnavailable$38.67M-$9.77MUnavailableUnavailable-$13.47M-$11.42MUnavailableUnavailable
Stock-based compensation$3.55MUnavailable$1.95M$2.19MUnavailableUnavailable$1.57M$2.00MUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable$170.00K$200.00KUnavailableUnavailable

Derived

Alto Neuroscience, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-31
Free cash flow-$19.76MUnavailable-$11.52M-$9.92MUnavailableUnavailable-$13.53M-$12.73MUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio14.85xUnavailable15.69x15.42xUnavailableUnavailable16.92x13.09xUnavailableUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.06xUnavailable0.11x0.18xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open ANRO in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-12View SEC filing
10-Q · Filed 2026-05-13View SEC filing
10-K · Filed 2026-03-16View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing
10-Q · Filed 2025-05-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

gross profit bridgeinconsistent2026-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2026-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.